ERBB2 and triple-negative breast carcinoma: Research has focused on understanding the mechanisms responsible for this resistance, particularly in aggressive triple-negative breast cancer (TNBC), though resistance in HER2+ and ER+/HER2− subtypes has also been extensively investigated.